The aim of our study was the evaluation of the effects of cigarette smoking on ambulatory blood pressure (ABP) in normotensive subjects participating to a cardiovascular prevention program. All subjects were followed up for an average time of 97742 months to assess the event of hypertension development. Prevalence of hypertension development was higher in smokers even if regression logistic analysis was not able to predict hypertension development.
Cigarette smoking is a powerful risk factor for the development of cardiovascular disease, but it is not a risk factor for the development of sustained arterial hypertension. Heavy cigarette smoking in experimental conditions is associated with a persistent rise in blood pressure (BP) and also with an increase in BP variability, as documented by ABP monitoring (ABPM), 1,2 but the impact of smoking habit in the eventual development of established hypertension has been shown only in a study on 183 selected Swedish aviators. 3 On the other hand, a prospective Japanese epidemiological study 4 has demonstrated that the cumulative incidence of hypertension development in smokers is lower than in non-and ex-smokers and is not related to difference in body mass index (BMI). Such conflicting findings can be explained by the fact that clinic BP measurements at study entry and during the follow-up are performed in smoke-free medical facilities. To obtain real-life information on the effects of cigarette smoking on BP in normotensives, it is necessary to measure BP throughout the day by means of ABPM and to follow-up subjects for a long time span.
From the database of a cardiovascular primary prevention program, we randomly and retrospectively selected 60 normotensive non-diabetic subjects (33 men and 27 women, age 50715 years). To perform a case-control study, the population was divided into two groups matched as closely as possible for age, gender, BMI and total cholesterol, selecting two non-smokers for each smoker to increase study power. 5 Thus, we obtained a group of 20 smokers (11 men and 9 women, age 50715 years) and a control group of 40 non-smokers (22 men and 18 women, age 50715 years). All subjects, participating in the cardiovascular prevention program and in this particular study, were patients of the National Health Service and gave their written informed consent for medical and scientific use of their personal data in an anonymous form. Ethical approval was not required because the study was considered 'observational' and not 'experimental' by the local Health Authority. Smoking was defined as a consumption of 20 or more cigarettes per day. All smokers started to smoke as teenagers with an average consumption of 382 packs per year. Frequency of smoking and current status of smoker were assessed through the clinical notes of the referring family physicians. All control non-smokers declared to be lifetime nonsmokers.
The referral office BP (OBP) (131/8276/6 in nonsmokers vs 134/8375/5 in smokers, nonsignificant (NS)) was measured by the family physicians with a standard mercury sphygmomanometer taking two readings spaced by 2 min and averaging the measurements.
All subjects, who had normal physical examination and electrocardiogram (ECG) and no history of hypertension or other cardiovascular disease, underwent ABPM by means of Spacelabs 90207 recorders (Spacelabs, Redmond, WA, USA), set to take automatic readings every 15 min during daytime (that is, waking period according to diaries) and every 20 min during nighttime (that is, sleeping period according to diaries). The ABPM recorders, validated according to the British Hypertension Society protocol, 6 were calibrated by simultaneous measurement with a mercury column at the start of each recording. All recordings were carried out on a working day and the following night, with no restriction on daily activities.
Twenty-three BP and heart rate (HR) variables were measured or derived and used in this study: 24-h, day and night systolic/diastolic BP, pulse pressure, HR and their s.d. as a measure of variability, dipper status (that is, a fall in BP during sleep X10%), ambulatory hypertension defined according to the criteria of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) (daytime ABP 4135/85 mm Hg) 7 or the European Society of Hypertension/European Society of Cardiology (ESH/ESC) guidelines (24-h ABP 4125/80 mm Hg). 8 All subjects were followed up for 97742 months by their family physicians at 6-month or 1-year intervals to report the event of rise in BP levels (generally above 145/95 mm Hg) that required antihypertensive drug treatment.
A power calculation was undertaken and showed that the study was able to detect differences in hypertension development between the two groups. Statistical analysis was performed by the BMDP statistical software 2.0 (Statistical Solutions, Cork, Ireland). Differences between groups were compared by Fisher's exact probability test for categorical variables and Mann-Whitney test for quantitative variables. The follow-up outcome was examined by Kaplan-Meier survival (that is, event-free) analysis; differences between survival curves were assessed by Breslow test. Stepwise logistic regression analysis was performed in order to evaluate variables that could predict hypertension development. Results with a P-value o0.05 were accepted as statistically significant.
All measured BP and HR variables were not statistically different between groups. Among derived variables, s.d. of 24-h systolic and diastolic BP, s.d. of daytime diastolic BP and prevalence of ambulatory hypertension defined according to the JNC 7 were statistically higher in smokers (all Po0.05). Even if logistic regression analysis did not find variables able to predict development of established hypertension, 12 subjects in the group of smokers and seven in the group of non-smokers developed hypertension in the follow-up (Po0.01) and time-to-event (that is, hypertension development) was statistically shorter (Po0.05) in smokers (79744 months) than in non-smokers (107738 months).
The event-free survival curves of study groups are illustrated in Figure 1 and the Breslow test gave a statistically significant result (P ¼ 0.001).
In our study, only BP variability expressed as s.d. and prevalence of ambulatory hypertension defined according to the daytime threshold of the JNC 7 7 were statistically higher in smokers. Conversely, the definition of ambulatory hypertension according to the 24-h threshold of the ESH/ESC guidelines 8 was not representative of the effects of cigarette smoking on ABP.
Moreover, in this study we showed that normotensive smokers are more prone to develop hypertension in a shorter time span than normotensive non-smokers and, thus, cigarette smoking could be a risk factor for the development of hypertension even if multivariate analysis did not find any variable that could predict the event. This flaw could be due to the limited sample of the study population.
In conclusion, the results of our ABPM study in normotensive smoking and non-smoking subjects without clinical and/or ECG signs of heart disease showed a prevalence of daytime ambulatory hypertension in smoking individuals. Consequently, 7/20 smokers (35%) could be considered already hypertensive and eventually be treated accordingly if diagnosis and treatment of BP elevation were guided by ABP values and not by OBP readings. In other words, these subjects could be regarded as 'masked hypertensives', that is, individuals who have clinic BP readings in the normal range but who are hypertensives according to ABPM. 9 Subjects in whom masked hypertension could be suspected include those who have other cardiovascular risk factors, such as central obesity or smoking, and predictors of hypertension development as increased alcohol consumption or family history of hypertension, 9 issues that were not investigated in the present study and could explain study results.
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